Systemic Lupus Erythematous SLE Drugs Market

Publish Date: Jun 2022

Report Code: FMI1913A

Publisher: Future Markets Insights

Single User License: $5000

Explore Our Services

Already a member? Login here.

Report Highlights

Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the immune system to mistakenly attack health body tissue. In SLE, body immune system can affect any part of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever, Raynaud’s phenomenon, livedo reticularis, thrombosis, and myositis.

It is also known as a disease of flare-ups and remissions and can range from mild to life threatening severity. It is also called as drug-induced lupus erythematosus due to common observation against drugs such as isoniazid, hydralazine and procainamide. Currently, there is no complete treatment for SLE. While only two biologic agents have been approved by FDA to treat SLE, synthetic drugs are still the mainstay of therapy in SLE. Based on available evidence, azathioprine and mycophenolate mofetil are the drugs of first choice. Hydroxychloroquine should be considered an anchor drug in SLE because of the multiple beneficial effects of this agent.

Systemic Lupus Erythematous (SLE) Drugs Market:  Drivers & Restraints                               

Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major drivers for global systemic erythematous drugs market are development of novel SLE therapies, increasing availability of bio similar drugs and increasing support for emerging research areas for new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment as well as consistent research and development processes for novel drug molecules are important drivers for global lupus erythematous market. Additionally, safety and quality of systemic lupus erythematous controlling therapy may possibly be a challenge for the growth of the global systemic lupus erythematous drugs market.

Moreover, numerous public awareness programs targeted to increase awareness levels are also being accompanied. For instance, Lupus Foundation of America (LFA) has been implementing various projects to increase central support for SLE research and services to support people and families affected by SLE. However, serious side effectswith steroids, sensitivity with antibiotics, limited usage of Benlysta for severe SLE patients, and stringent regulatory approvals for new treatment options with better levels of efficacy and safety are obstructing the global systemic lupus erythematous drugs market.

Systemic Lupus Erythematous (SLE) Drugs Market:  Segmentation

The global systemic lupus erythematous drugs market is classified on the basis of molecule and region.

Based on type of molecule, the global systemic lupus erythematous drugs market is segmented into the following:

  • Corticosteroids
  • Prednisone
  • Cortisone
  • Hydrocortisone
  • Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
  • Over-the-counter NSAIDs include
  • Ibuprofen (Motrin)
  • Naproxen (Naprosyn)
  • Prescription versions include
  • Indomethacin (Indocin)
  • Nabumetone (RELAFEN)
  • Celecoxib (Celebrex)
  • Anti-Inflammatories
  • Aspirin
  • Acetaminophen (Tylenol)
  • Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
  • Hydroxychloroquine (Plaquenil).
  • Cyclosporine (Gengraf, Neoral, Sandimmune)
  • Azathioprine (Azasan, Imuran)
  • Antimalarials
  • Chloroquine (Aralen)
  • Hydroxychloroquine (Plaquenil)
  • BLyS-specific Inhibitors or Monoclonal Antibodies (MAbS)
  • Belimumab (Benlysta)
  • Immunosuppressive Agents/Immune Modulators
  • Azathioprine (Imuran)
  • Methotrexate (Rheumatrex)
  • Cyclophosphamide (Cytoxan)
  • Anticoagulants
  • Low-dose aspirin
  • Heparin (Calciparine, Liquaemin)
  • Warfarin (Coumadin)
  • Systemic Lupus Erythematous (SLE) Drugs Market:  Overview

Global systemic lupus erythematous drugs market growth is fast in North American region and is estimated to project remarkable CAGR growth throughout forecast period. In North America, the SLE is more prevalent among Hispanics, Asians, and Native Americans according to Centers for Disease Control and Prevention (CDC). The second largest and fastest growing global systemic lupus erythematous drugs market is Europe and is projected to reach nearly US$ 550 Mn and register a double digit CAGR due to higher prevalence of SLE in Europe. Among the European countries Sweden, Iceland, Spain had the highest prevalence according to Lupus Journal article, published in 2006. A drug called hydroxychloroquine being the last drug was approved by FDA in 1955 for SLE treatment.

Recently, a drug called belimumab has been approved by FDA after 50 years long gap specifically for SLE on March 9, 2011. It is the first ever targeted biological drug for the treatment of SLE patients developed by Human Genome Sciences Inc. in collaboration with GlaxoSmithKline. It will be the primary driver for global systemic lupus erythematous drugs market growth in the US, France, Germany, Italy Spain, the UK and Japan. Benlysta will lead market sales in coming years because of its excellent safety profile as well as proven efficacy in clinical trials. NSAIDS such as Ibuprofen and aspirin are widely prescribed drugs for suppressing symptoms of SLE. Immunosuppressants by Roche (CellCept (Mycophenolate mofetil), by Novartis (Neoral (Cyclosporine)), by GSK (Imuran (Azathioprine)) are also commonly prescribed for SLE treatment. Additionally, the entry of four first-in-class (FIC) biologics such as Bristol-Myers Squibb’s Orencia (abatacept), atacicept, epratuzumab and LY2127399 are anticipated to show a major role in the expansion of the global systemic lupus erythematous drugs market. 

Systemic Lupus Erythematous (SLE) Drugs Market:  Key Players

The global systemic lupus erythematous drugs market key players are Anthera Pharmaceuticals BMS, GSK, ImmuPharma, Merck Serono, UCB, Amgen, HGS, Immunomedics, Johnson and Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, accessories and applications.

The report covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Market Size
  • Supply & Demand
  • Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain

Regional analysis includes

  • North America (U.S., Canada)
  • Latin America (Mexico, Brazil)
  • Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, BENELUX)
  • Eastern Europe (Poland, Russia)
  • Asia Pacific (China, India, ASEAN, Australia & New Zealand)
  • Japan
  • Middle East and Africa (GCC and S. Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2022-2032
Units considered $ Million
Segments covered By Molecule Type, By Distribution Channel, By Region, By Country
Industry covered Healthcare
Countries covered North America, Latin America, Asia Pacific, MEA, Europe
Companies studied
  • Anthera Pharmaceuticals BMS
  • HGS
  • GSK
  • ImmuPharma
  • Merck Serono
  • Amgen
  • UCB
  • MedImmune
  • Immunomedics
  • Johnson and Johnson
  • Teva Pharmaceutical Industries.
  • Sanofi

Report Highlights:

  • Detailed overview of parent market
  • Changing market dynamics in the industry
  • In-depth market segmentation
  • Historical, current and projected market size in terms of volume and value
  • Recent industry trends and developments
  • Competitive landscape
  • Strategies of key players and products offered
  • Potential and niche segments, geographical regions exhibiting promising growth
  • A neutral perspective on market performance
  • Must-have information for market players to sustain and enhance their market footprint.

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

  • Table 1 : Global Market Value (US$ Mn) Forecast by Region, 2017-2032
  • Table 2 : Global Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
  • Table 3 : Global Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Table 4 : North America Market Value (US$ Mn) Forecast by Country, 2017-2032
  • Table 5 : North America Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
  • Table 6 : North America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Table 7 : Latin America Market Value (US$ Mn) Forecast by Country, 2017-2032
  • Table 8 : Latin America Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
  • Table 9 : Latin America Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Table 10 : Europe Market Value (US$ Mn) Forecast by Country, 2017-2032
  • Table 11 : Europe Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
  • Table 12 : Europe Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Table 13 : East Asia Market Value (US$ Mn) Forecast by Country, 2017-2032
  • Table 14 : East Asia Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
  • Table 15 : East Asia Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Table 16 : South Asia & Pacific Market Value (US$ Mn) Forecast by Country, 2017-2032
  • Table 17 : South Asia & Pacific Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
  • Table 18 : South Asia & Pacific Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Table 19 : MEA Market Value (US$ Mn) Forecast by Country, 2017-2032
  • Table 20 : MEA Market Value (US$ Mn) Forecast by Molecule Type, 2017-2032
  • Table 21 : MEA Market Value (US$ Mn) Forecast by Distribution Channel, 2017-2032
  • Figure 1 : Global Market Value (US$ Mn) by Molecule Type, 2022-2032
  • Figure 2 : Global Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 3 : Global Market Value (US$ Mn) by Region, 2022-2032
  • Figure 4 : Global Market Value (US$ Mn) Analysis by Region, 2017-2032
  • Figure 5 : Global Market Value Share (%) and BPS Analysis by Region, 2022-2032
  • Figure 6 : Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032
  • Figure 7 : Global Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
  • Figure 8 : Global Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
  • Figure 9 : Global Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
  • Figure 10 : Global Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 11 : Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 12 : Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 13 : Global Market Attractiveness by Molecule Type, 2022-2032
  • Figure 14 : Global Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 15 : Global Market Attractiveness by Region, 2022-2032
  • Figure 16 : North America Market Value (US$ Mn) by Molecule Type, 2022-2032
  • Figure 17 : North America Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 18 : North America Market Value (US$ Mn) by Country, 2022-2032
  • Figure 19 : North America Market Value (US$ Mn) Analysis by Country, 2017-2032
  • Figure 20 : North America Market Value Share (%) and BPS Analysis by Country, 2022-2032
  • Figure 21 : North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 22 : North America Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
  • Figure 23 : North America Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
  • Figure 24 : North America Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
  • Figure 25 : North America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 26 : North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 27 : North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 28 : North America Market Attractiveness by Molecule Type, 2022-2032
  • Figure 29 : North America Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 30 : North America Market Attractiveness by Country, 2022-2032
  • Figure 31 : Latin America Market Value (US$ Mn) by Molecule Type, 2022-2032
  • Figure 32 : Latin America Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 33 : Latin America Market Value (US$ Mn) by Country, 2022-2032
  • Figure 34 : Latin America Market Value (US$ Mn) Analysis by Country, 2017-2032
  • Figure 35 : Latin America Market Value Share (%) and BPS Analysis by Country, 2022-2032
  • Figure 36 : Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 37 : Latin America Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
  • Figure 38 : Latin America Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
  • Figure 39 : Latin America Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
  • Figure 40 : Latin America Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 41 : Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 42 : Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 43 : Latin America Market Attractiveness by Molecule Type, 2022-2032
  • Figure 44 : Latin America Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 45 : Latin America Market Attractiveness by Country, 2022-2032
  • Figure 46 : Europe Market Value (US$ Mn) by Molecule Type, 2022-2032
  • Figure 47 : Europe Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 48 : Europe Market Value (US$ Mn) by Country, 2022-2032
  • Figure 49 : Europe Market Value (US$ Mn) Analysis by Country, 2017-2032
  • Figure 50 : Europe Market Value Share (%) and BPS Analysis by Country, 2022-2032
  • Figure 51 : Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 52 : Europe Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
  • Figure 53 : Europe Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
  • Figure 54 : Europe Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
  • Figure 55 : Europe Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 56 : Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 57 : Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 58 : Europe Market Attractiveness by Molecule Type, 2022-2032
  • Figure 59 : Europe Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 60 : Europe Market Attractiveness by Country, 2022-2032
  • Figure 61 : East Asia Market Value (US$ Mn) by Molecule Type, 2022-2032
  • Figure 62 : East Asia Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 63 : East Asia Market Value (US$ Mn) by Country, 2022-2032
  • Figure 64 : East Asia Market Value (US$ Mn) Analysis by Country, 2017-2032
  • Figure 65 : East Asia Market Value Share (%) and BPS Analysis by Country, 2022-2032
  • Figure 66 : East Asia Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 67 : East Asia Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
  • Figure 68 : East Asia Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
  • Figure 69 : East Asia Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
  • Figure 70 : East Asia Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 71 : East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 72 : East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 73 : East Asia Market Attractiveness by Molecule Type, 2022-2032
  • Figure 74 : East Asia Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 75 : East Asia Market Attractiveness by Country, 2022-2032
  • Figure 76 : South Asia & Pacific Market Value (US$ Mn) by Molecule Type, 2022-2032
  • Figure 77 : South Asia & Pacific Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 78 : South Asia & Pacific Market Value (US$ Mn) by Country, 2022-2032
  • Figure 79 : South Asia & Pacific Market Value (US$ Mn) Analysis by Country, 2017-2032
  • Figure 80 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Country, 2022-2032
  • Figure 81 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 82 : South Asia & Pacific Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
  • Figure 83 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
  • Figure 84 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
  • Figure 85 : South Asia & Pacific Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 86 : South Asia & Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 87 : South Asia & Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 88 : South Asia & Pacific Market Attractiveness by Molecule Type, 2022-2032
  • Figure 89 : South Asia & Pacific Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 90 : South Asia & Pacific Market Attractiveness by Country, 2022-2032
  • Figure 91 : MEA Market Value (US$ Mn) by Molecule Type, 2022-2032
  • Figure 92 : MEA Market Value (US$ Mn) by Distribution Channel, 2022-2032
  • Figure 93 : MEA Market Value (US$ Mn) by Country, 2022-2032
  • Figure 94 : MEA Market Value (US$ Mn) Analysis by Country, 2017-2032
  • Figure 95 : MEA Market Value Share (%) and BPS Analysis by Country, 2022-2032
  • Figure 96 : MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032
  • Figure 97 : MEA Market Value (US$ Mn) Analysis by Molecule Type, 2017-2032
  • Figure 98 : MEA Market Value Share (%) and BPS Analysis by Molecule Type, 2022-2032
  • Figure 99 : MEA Market Y-o-Y Growth (%) Projections by Molecule Type, 2022-2032
  • Figure 100 : MEA Market Value (US$ Mn) Analysis by Distribution Channel, 2017-2032
  • Figure 101 : MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2022-2032
  • Figure 102 : MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2022-2032
  • Figure 103 : MEA Market Attractiveness by Molecule Type, 2022-2032
  • Figure 104 : MEA Market Attractiveness by Distribution Channel, 2022-2032
  • Figure 105 : MEA Market Attractiveness by Country, 2022-2032

Future Market Insights is the premier provider of market intelligence and consulting services, serving client in over 160 countries. FMI is headquartered in London, the global financial capital and has delivery centers in the U.S. and India. FMI's research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure that our clients prepare for the evolving needs of their customers. FMI's team of over 200 research analysts provides market intelligence at global, regional, and country levels. Our analysts are committed to provide independent insights, relying on our cognitive training modules, which conditions them to look at data objectively and unbiasedly. Others you can use from the file Allen just shared when those will be made live.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Systemic Lupus Erythematous SLE Drugs Market